Ultragenyx Pharmaceutical Class Action Reminder for Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy RARE?
Source: Businesswire
- Lawsuit Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for violations of securities laws during the period from August 3, 2023, to December 26, 2025, with a deadline to contact the firm by April 6, 2026.
- False Statements: The complaint alleges that Ultragenyx made false and misleading statements regarding its drug candidate's effects on Osteogenesis Imperfecta patients, creating a misleadingly optimistic view of the company's prospects among investors.
- Study Failure: The Phase III ORBIT study revealed that the company failed to achieve a statistically significant reduction in annualized fracture rate, indicating that its prior public statements were false and materially misleading, resulting in investor losses.
- Investor Losses: As the market learned the truth about Ultragenyx, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit to recover their losses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RARE
Wall Street analysts forecast RARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RARE is 61.65 USD with a low forecast of 35.00 USD and a high forecast of 120.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 24.690
Low
35.00
Averages
61.65
High
120.00
Current: 24.690
Low
35.00
Averages
61.65
High
120.00
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ultragenyx Reports Long-Term Data on UX111 for Sanfilippo Syndrome
- Clinical Trial Results: Ultragenyx announced long-term data for UX111, showing a significant 23.2-point improvement (p<0.0001) in Bayley-III cognitive raw scores for 17 patients under two years old compared to natural history data during 24-60 months, indicating substantial efficacy of the gene therapy in enhancing cognitive function.
- Functional Improvements: In addition to cognitive gains, caregiver-reported outcomes using Vineland 3 demonstrated comparable improvements in communication, motor, and personal subdomains, further validating the clinical benefits of UX111.
- Biomarker Enhancements: As of the September 2025 cutoff, the median reduction in cerebrospinal fluid heparan sulfate (CSF-HS) was 63.98% (p<0.001), with 88.2% of treated children achieving a 50% or greater reduction, underscoring the treatment's effectiveness.
- FDA Application Progress: These long-term data have been included in the resubmitted Biologics License Application (BLA), with the company anticipating an accelerated review by the FDA, expected to conclude in the third quarter of 2026, which could significantly enhance UX111's market prospects.
See More
Ultragenyx Pharmaceutical Class Action Lawsuit Notification
- Lawsuit Background: Kahn Swick & Foti LLC has notified investors in Ultragenyx Pharmaceutical of a class action lawsuit due to alleged securities fraud occurring between August 3, 2023, and December 26, 2025, aimed at recovering losses for affected investors.
- Stock Price Plunge: Following the December 26, 2025 announcement that setrusumab (UX143) failed to show a statistically significant reduction in fracture rates in its Phase 3 trials, Ultragenyx's stock price plummeted approximately 42%, from $34.19 to $19.72, indicating severe market concerns about the company's future.
- Legal Action Deadline: Investors who suffered losses during the relevant period have until April 6, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving in this role.
- Law Firm Background: Kahn Swick & Foti is recognized as one of the premier boutique securities litigation firms in the U.S., ranked among the top 10 nationally based on total settlement value, and specializes in recovering losses for investors affected by corporate fraud.
See More
Ultragenyx Pharmaceutical Class Action Reminder for Investors
- Lawsuit Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for violations of securities laws during the period from August 3, 2023, to December 26, 2025, with a deadline to contact the firm by April 6, 2026.
- False Statements: The complaint alleges that Ultragenyx made false and misleading statements regarding its drug candidate's effects on Osteogenesis Imperfecta patients, creating a misleadingly optimistic view of the company's prospects among investors.
- Study Failure: The Phase III ORBIT study revealed that the company failed to achieve a statistically significant reduction in annualized fracture rate, indicating that its prior public statements were false and materially misleading, resulting in investor losses.
- Investor Losses: As the market learned the truth about Ultragenyx, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit to recover their losses.
See More
Ultragenyx Faces Shareholder Class Action Lawsuit
- Lawsuit Background: Ultragenyx Pharmaceutical Inc. is facing a shareholder class action lawsuit for allegedly issuing false and misleading statements regarding its Phase III Orbit and Cosmic studies, which could significantly impact the company's reputation and stock price.
- Investor Losses: The lawsuit targets investors who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, encouraging those who experienced significant losses to contact legal counsel, potentially leading to increased participation in the lawsuit.
- Legal Representation: Holzer & Holzer, LLC, a highly regarded law firm in securities litigation, focuses on providing vigorous legal support to shareholders, which may have far-reaching implications for Ultragenyx's future legal liabilities.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by April 6, 2026, and this time constraint may affect the level of participation and outcomes of the lawsuit, further influencing Ultragenyx's market performance.
See More
Ultragenyx Faces Class Action Lawsuit Over Stock Misrepresentation
- Class Action Initiation: Robbins Geller law firm announces a class action lawsuit against Ultragenyx Pharmaceutical, representing stock purchasers from August 3, 2023, to December 26, 2025, alleging violations of the Securities Exchange Act by top executives.
- False Statement Allegations: The lawsuit claims that Ultragenyx misled investors by failing to disclose risks associated with the Phase III Orbit study, where patients did not achieve a statistically significant reduction in annualized fracture rates, impacting stock price perception.
- Stock Price Plunge: Following the announcement on July 9, 2025, and December 29, 2025, regarding the failure to achieve statistical significance in study results, Ultragenyx's stock fell over 25% and 42% respectively, indicating a severe loss of investor confidence.
- Investor Rights Protection: Under the Private Securities Litigation Reform Act, any investor who purchased Ultragenyx stock during the class period can seek to be appointed as lead plaintiff, ensuring their rights are represented in the lawsuit.
See More
Ultragenyx Pharmaceutical Accused of Misleading Investors
- Class Action Filed: Robbins LLP has initiated a class action against Ultragenyx Pharmaceutical (NASDAQ: RARE) on behalf of all investors who purchased shares between August 3, 2023, and December 26, 2025, indicating strong investor concern over potential misleading actions by the company.
- Study Results Failure: The complaint alleges that Ultragenyx misrepresented the efficacy of setrusumab in its Phase III Orbit and Cosmic studies, claiming it would significantly reduce annualized fracture rates in Osteogenesis Imperfecta patients, but ultimately failed to achieve statistical significance, leading to a sharp decline in investor confidence.
- Stock Price Plunge: Following the announcement of study failures on December 29, 2025, Ultragenyx's stock price plummeted from $34.19 per share on December 26 to $19.72 on December 29, marking a staggering 42.32% drop in just one day, reflecting the market's pessimistic outlook on the company's future.
- Investor Rights Protection: Robbins LLP encourages investors interested in serving as lead plaintiffs in the class action to reach out, demonstrating the firm's commitment to protecting shareholder rights and holding companies accountable for their actions.
See More
Ultragenyx Reports Long-Term Data on UX111 for Sanfilippo Syndrome
- Clinical Trial Results: Ultragenyx announced long-term data for UX111, showing a significant 23.2-point improvement (p<0.0001) in Bayley-III cognitive raw scores for 17 patients under two years old compared to natural history data during 24-60 months, indicating substantial efficacy of the gene therapy in enhancing cognitive function.
- Functional Improvements: In addition to cognitive gains, caregiver-reported outcomes using Vineland 3 demonstrated comparable improvements in communication, motor, and personal subdomains, further validating the clinical benefits of UX111.
- Biomarker Enhancements: As of the September 2025 cutoff, the median reduction in cerebrospinal fluid heparan sulfate (CSF-HS) was 63.98% (p<0.001), with 88.2% of treated children achieving a 50% or greater reduction, underscoring the treatment's effectiveness.
- FDA Application Progress: These long-term data have been included in the resubmitted Biologics License Application (BLA), with the company anticipating an accelerated review by the FDA, expected to conclude in the third quarter of 2026, which could significantly enhance UX111's market prospects.
See More
Ultragenyx Pharmaceutical Class Action Lawsuit Notification
- Lawsuit Background: Kahn Swick & Foti LLC has notified investors in Ultragenyx Pharmaceutical of a class action lawsuit due to alleged securities fraud occurring between August 3, 2023, and December 26, 2025, aimed at recovering losses for affected investors.
- Stock Price Plunge: Following the December 26, 2025 announcement that setrusumab (UX143) failed to show a statistically significant reduction in fracture rates in its Phase 3 trials, Ultragenyx's stock price plummeted approximately 42%, from $34.19 to $19.72, indicating severe market concerns about the company's future.
- Legal Action Deadline: Investors who suffered losses during the relevant period have until April 6, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving in this role.
- Law Firm Background: Kahn Swick & Foti is recognized as one of the premier boutique securities litigation firms in the U.S., ranked among the top 10 nationally based on total settlement value, and specializes in recovering losses for investors affected by corporate fraud.
See More
Ultragenyx Pharmaceutical Class Action Reminder for Investors
- Lawsuit Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for violations of securities laws during the period from August 3, 2023, to December 26, 2025, with a deadline to contact the firm by April 6, 2026.
- False Statements: The complaint alleges that Ultragenyx made false and misleading statements regarding its drug candidate's effects on Osteogenesis Imperfecta patients, creating a misleadingly optimistic view of the company's prospects among investors.
- Study Failure: The Phase III ORBIT study revealed that the company failed to achieve a statistically significant reduction in annualized fracture rate, indicating that its prior public statements were false and materially misleading, resulting in investor losses.
- Investor Losses: As the market learned the truth about Ultragenyx, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to join the lawsuit to recover their losses.
See More
Ultragenyx Faces Shareholder Class Action Lawsuit
- Lawsuit Background: Ultragenyx Pharmaceutical Inc. is facing a shareholder class action lawsuit for allegedly issuing false and misleading statements regarding its Phase III Orbit and Cosmic studies, which could significantly impact the company's reputation and stock price.
- Investor Losses: The lawsuit targets investors who purchased Ultragenyx shares between August 3, 2023, and December 26, 2025, encouraging those who experienced significant losses to contact legal counsel, potentially leading to increased participation in the lawsuit.
- Legal Representation: Holzer & Holzer, LLC, a highly regarded law firm in securities litigation, focuses on providing vigorous legal support to shareholders, which may have far-reaching implications for Ultragenyx's future legal liabilities.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by April 6, 2026, and this time constraint may affect the level of participation and outcomes of the lawsuit, further influencing Ultragenyx's market performance.
See More
Ultragenyx Faces Class Action Lawsuit Over Stock Misrepresentation
- Class Action Initiation: Robbins Geller law firm announces a class action lawsuit against Ultragenyx Pharmaceutical, representing stock purchasers from August 3, 2023, to December 26, 2025, alleging violations of the Securities Exchange Act by top executives.
- False Statement Allegations: The lawsuit claims that Ultragenyx misled investors by failing to disclose risks associated with the Phase III Orbit study, where patients did not achieve a statistically significant reduction in annualized fracture rates, impacting stock price perception.
- Stock Price Plunge: Following the announcement on July 9, 2025, and December 29, 2025, regarding the failure to achieve statistical significance in study results, Ultragenyx's stock fell over 25% and 42% respectively, indicating a severe loss of investor confidence.
- Investor Rights Protection: Under the Private Securities Litigation Reform Act, any investor who purchased Ultragenyx stock during the class period can seek to be appointed as lead plaintiff, ensuring their rights are represented in the lawsuit.
See More
Ultragenyx Pharmaceutical Accused of Misleading Investors
- Class Action Filed: Robbins LLP has initiated a class action against Ultragenyx Pharmaceutical (NASDAQ: RARE) on behalf of all investors who purchased shares between August 3, 2023, and December 26, 2025, indicating strong investor concern over potential misleading actions by the company.
- Study Results Failure: The complaint alleges that Ultragenyx misrepresented the efficacy of setrusumab in its Phase III Orbit and Cosmic studies, claiming it would significantly reduce annualized fracture rates in Osteogenesis Imperfecta patients, but ultimately failed to achieve statistical significance, leading to a sharp decline in investor confidence.
- Stock Price Plunge: Following the announcement of study failures on December 29, 2025, Ultragenyx's stock price plummeted from $34.19 per share on December 26 to $19.72 on December 29, marking a staggering 42.32% drop in just one day, reflecting the market's pessimistic outlook on the company's future.
- Investor Rights Protection: Robbins LLP encourages investors interested in serving as lead plaintiffs in the class action to reach out, demonstrating the firm's commitment to protecting shareholder rights and holding companies accountable for their actions.
See More
